FACIO-SCAPULO-HUMERAL DYSTROPHY
Clinical trials for FACIO-SCAPULO-HUMERAL DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new FACIO-SCAPULO-HUMERAL DYSTROPHY trials appear
Sign up with your email to follow new studies for FACIO-SCAPULO-HUMERAL DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial targets root cause of rare Muscle-Wasting disease
Disease control Recruiting nowThis early-stage study is testing a new drug called ARO-DUX4 in adults and adolescents with FSHD1, a genetic muscle-wasting disease. The main goals are to see if the drug is safe, how the body processes it, and if it affects the target in the muscle. Participants will receive the…
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Apr 04, 2026 01:35 UTC
-
Breakthrough drug trial offers hope for rare muscle disease
Disease control Recruiting nowThis study is testing an experimental drug called AOC 1020 for people with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 participants will receive either the drug or a placebo via IV infusion every six weeks …
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC